This symposium was held in Trento, Italy, on June 19-21, 2014, and was focused on advances in biology, physiology, and pathology of neoplasms affected by hormones, especially breast and prostate cancers. The stem cell function, the genetic and epigenetic interactions with hormones, the mechanisms of estrogen receptor transcription, biochemical markers and therapeutic targets in breast cancer, promotion of breast cancer carcinogenesis by progesterone, the basis for prostate cancer progression and the relevance of DNA repair processes, androgen receptor programming during prostate carcinogenesis, the metabolic stress role in tumor survival, and the diagnostic use of imaging in prostate cancer were discussed. Cancer Res; 75 (7) 
Mechanisms of Tumor Cell Hormone Responsiveness
Sohail Tovazoie (The Rockefeller University, New York, NY) indicated that small RNAs, ApoE, and LRP comprise a druggable antimetastatic melanoma network. Specific microRNA sets govern metastatic progression of breast cancer and melanoma. MiR199a-5p, miR-199a-3p, and miR-1908 are highly overexpressed in metastatic melanoma cells and are metastatic promoters and convergently target the secreted protein ApoE, which is a strong suppressor of melanoma invasion, endothelial recruitment, and metastatic colonization. ApoE is a secreted protein that mediates these effects through its engagement of the LRP1 receptor on melanoma cells and LRP8 receptor on endothelial cell. Transcriptional ApoE induction (through pharmacologic activation of the Liver-X nuclear hormone receptor) inhibits tumor growth, endothelial cell proliferation, and metastasis.
Miguel Beato (Centre de Regulacio Genomica, Barcelona, Spain) discussed the structural dynamics in hormonal gene regulation. Breast cancer cells respond to steroid hormones by extensive changes in 4,000 genes' expression. The T47D cell response to progestins showed that the organization in nucleosomes of the DNA sequences recognized by the progesterone receptor (PR) is key for the initiation of chromatin remodeling response, which depends on PR-associated enzymatic activities. The genome division in consecutive topological association domains (TAD) contributes to coordination of hormonal responses. Repressed TADs compact in response to hormone and the interactions among their genes decrease, whereas activated TADs expand and the interactions among their genes increase. These findings underline the importance of the various chromatin structure levels for gene regulation and lead to the proposal that TADs behave as "regulons" in the cell response to external signals.
Hormonal Signaling in Breast Cancer
Myles Brown (Dana Farber Cancer Institute, Boston, MA) outlined the genetic and epigenetic determinations of hormone dependence. Specific drugs targeting the enzymes responsible for steroid synthesis and the steroid receptors and the development of the estrogen receptor (ER) led to the first breast cancer predictive biomarker and the first molecularly defined therapeutic target. ER mutations can explain resistance to endocrine therapy in 20% of patients with advanced disease. These mutations activate the receptor in the absence of hormone and make it resistant to existing antagonists. They support the conclusion that the tumor-initiating cell is ER dependent. 
Translational Developments in HormoneDriven Breast Cancer
Rene Bernards (Nederland Cancer Center, Amsterdam, the Netherlands) described breast cancer molecular diagnostics. The genome takes center stage in key treatment decisions for breast cancer. Measurement of ER was the first diagnostic for a targeted cancer drug. Staining HER2 for the treatment with trastuzumab was also first used in breast cancer. A number of molecular diagnostic assays have been developed to help determine the risk of recurrence in breast cancer, including Mamma Print, OncotypeDx, and Prosigna.
Carlos Arteaga (Vanderbilt-Ingram Cancer Center, Nashville, TN) discussed the PI3K/AKT/TOR as a therapeutic target in breast cancer. Several drugs targeting the PI3K network have been developed. ATP mimetics that bind competitively and reversibly to the ATP-binding pocket of p110 isozime are in clinical development. These include pan-PI3K inhibitors, p110a-specific inhibitors, p110d-specific inhibitor CAL-101, and dual PI3K/mTOR inhibitors. The pan-PI3K and p110a-specific inhibitors are equally potent against p110a mutants. In recent phase I trials with dual inhibitors, few responses were observed in patients with and without detectable PI3K pathway mutations. Allosteric ATP-competitive pan-inhibitors of the three isoforms of AKT are being developed. Allosteric inhibitor MK-2206 binds to the AKT PH domain and/or hinge region to promote an inactive conformation of the AKT signaling in vivo, and suppresses growth of breast cancer xenografts harboring PIK3CA mutations or ERBB2 amplification. Phase I data showed that treatment with MK-2206 decreases P-AKT levels, in tumor cells, peripheral blood mononuclear cells, and hair follicles. Another approach to block this pathway has been the development of ATP-competitive inhibitors of the mTOR kinase. Dual PI3K7mTOR inhibitors have also been developed in the hope of overcoming the loss of feedback inhibition or PI3K activation.
Mitch Dowsett (Institute of Cancer Research, London, UK) described biomarkers of response and resistance to estrogen deprivation in breast cancer. Multiple metagenes representing proliferation and estrogen-responsive pathways were profoundly reduced by aromastase inhibitors, as were signaling pathways, potentially contributing to benefit from therapy. In contrast, expression of certain genes was significantly increased by treatment, suggesting that the resistance-relevant pathways are upregulated at early time point.
In ER-positive breast cancers treated for 5 years with tamoxifen, one can identify early recurrence at 5 years versus late recurrence at 10 years. A total of 1,327 genes predicted early versus late recurrence.
Pier Paolo Di Fiore (IFOM-IEO Campus, Milan, Italy) discussed one mechanism of coupling cell-fate determinations and tumor suppression in mammary stem cells. Numb is a protein that, by asymmetrically partitioning at mitosis, controls binary cell-fate decisions. In human breast cancers, there is frequent loss of Numb expression. The lack of Numb allows for unchecked signaling activity of the Notch receptor and causes attenuation of the p53 signaling pathway. This latter function is exerted through Numbmediated inhibition of the ubiquitinating function of the E3 ligase Mdm2 over p53. Thus, loss of Numb allows for the simultaneous activation of an oncogene (Notch) and attenuation of an oncosuppressor (p53), in a circuitry shown to be relevant to the subversion of homeostasis in the mammary stem cell compartment.
Hormonal Signaling in Prostate Cancer
Arul M. Chinnaiyan (Michigan Center for Translational Pathology, Ann Arbor, MI) discussed progress toward precision medicine for advanced prostate cancer MI-ONCOSEQ is a unique clinical sequencing program, which consists of three integrated projects: (i) "Clinical Genomic Study"; (ii) "Sequencing and Analysis" progresses, biospecimens with sequencing and analysis of tumors for point mutations, copy number changes, gene fusions and aberrant gene expression; (iii) "Ethics and Psychosocial Analysis." More than 250 adults and 40 children with cancer have been sequenced with return of results through a "precision medicine tumor board (PMTB)." Discoveries include the identification of a novel recurrent NAB2-STAT6 gene fusion in solitary fibrous tumors, a rare soft-tissue tumor rearrangement involving targetable FGFR in various cancers and identification of ESR1 mutations acquired after antiestrogen therapies. It was found that protein BRD 4 activates Myc and is a therapeutic target in prostate cancer.
Owen Witte (University of California, Los Angeles, Los Angeles CA) discussed multiple pathways that can be involved in prostate cancer progression to castration-resistance stage. Mouse and human benign prostate epithelial basal stem cells have been defined as one cell of origin that can respond to multiple stimuli to produce cancers, which are capable of maturing to more differentiated cell types, including luminal, squamous, and neuroendocrine phenotypes. Current work is focusing on the activation of specific kinase-driven pathways to provide new therapy targets in metastatic prostate cancer. Tyrosine phosphosylation is increased in castration-resistant prostate cancer despite low androgen receptor (AR) mutations.
Antonella Farsetti (Ist. Naz. Tumori Regina Elena, Rome) discussed estrogen/ER, hypoxia/ hypoxia-inducible factor (HIF), and NO/eNOS signaling in hormone-driven cancers. Nuclearized Roland Schuele (University of Freiburg Medical Center, Freiburg, Germany) discussed the physiopathology of the epigenetic histone lysine-specific demethylase LSD1, which is associated with AR in prostate and prostate cancer. Epigenetic control mechanisms serve as an additional layer in gene expression regulation. LSD1 removes mono-and dimethyl groups from H3K4 or H3K9, thereby causing either repression or activation of gene transcription. The roles of LSD1 in regulating chromatin organization and AR-dependent gene expression in prostate cells have been uncovered. The chromatin remodeler CHD1 binds to methylated histone and interacts with methylated LSD1, blocking ligand-induced AR recruitment.
Matthew Freedman (Dana Farber Cancer Institute, Boston, MA) outlined charting the AR cistrome in human prostate tissue. The genome-wide set of AR-binding sites was mapped in 21 normal and prostate cancer samples using chromatin immunoprecipitation followed by high-throughput sequencing: It was established that HOXB13 and FOXA1 reprogram the AR cistrome during prostate tumorigenesis. The identification of differential AR-binding sites between normal and tumor revealed key AR coregulators as well as AR target genes that distinguish indolent from aggressive prostate cancer.
Karen Knudsen (Thomas Jefferson University, Philadelphia, PA) discussed AR-DNA repair interplay in prostate cancer and their implications for disease progression. Alterations in DNA damage repair (DDR) pathways are common in sporadic prostate cancer, and alterations in these pathways may accord effective means of therapeutic intervention. First, alterations in genes whose functions are key for DNA repair increase in frequency as a disease-progression function. Second, the AR is a critical effector of DNA repair competence that alters the response to genotoxic insult in advanced prostate cancer. AR regulates the expression and activity of DNAPK, an enzyme that is key for repairing doublestrand DNA breaks, and a transcriptional modulator. Third, clinical trials revealed that therapeutic agents that target the DDR pathway are effective in treating advanced prostate cancer, consistent with the postulate that a subset of advanced tumors has altered DDR programs.
Translational Developments in HormoneDriven Prostate Cancer
William Hait (New Brunswick, NJ) discussed the metabolic stress relevance in cancer. Nutrient and growth factor deprivation, hypoxia, and low pH create metabolic demands that require cellular adaptations to sustain energy levels. Protein synthesis is a most notable energy consumer. Mounting evidence implicates control of protein synthesis as a survival mechanism for both normal and malignant cells. Autophagy conserves energy. Ca/ Calmodulin-dependent kinase activity differs in normal versus cancer cells; elongation factor-2 kinase, a downstream component of the PI3K/AKT pathway that behaves as a critical checkpoint in energy consumption, is phosphorylated only in tumors in the presence of Ca/Calmodulin and it inhibits protein translation. This kinase is inhibited by activated MTOR and S6K; its knockdown causes a decrease of autophagy. Starvation induces its activation. It regulates increases in peptide elongation in starvation. In prostate cancer, responses to enzobutamide are increased by a decrease of autophagy. Abiterone acetate is effective in castration-resistant prostate cancer (CRPC).
Srinivasan Yesnasubramanian (The Johns Hopkins University, Baltimore, MD) discussed androgen-induced double-stand breaks (DSB) in prostate cancer. Induction of AR-mediated transcriptional programs by androgen stimulation also involves DNA damage, DSB, and DSB repair proteins. The DSB can be mediated by topoisomerase TOP2B, which is recruited with AR to regulatory sites on target genes and is required for efficient transcriptional activation of these genes. If illegitimately repaired, such DSBs can contribute to cancer progression by promoting genetic instability and seeding formation of genomic rearrangements, such as the recurrent TMPRSS2-ERG fusion oncogene in prostate cancer. These androgen-induced TOP2B-mediated DSBs may be exploitable therapeutically. Short pulses of androgen stimulating in the backdrop of androgen depletion therapy could selectively sensitize prostate cancer cells to DNA damaging agents or to DNA repair inhibitors.
Robert Reiter (University of California, Los Angeles) outlined the usage of PET and optical imaging of prostate cancer with engineered antibodies. The utility of engineered antibody fragments targeting major prostate cancer antigens, such as prostate stem cell antigen (PSCA) and prostate membrane antigen (PSMA), to image prostate cancer was explored. Engineered antibody fragments retain the specificity of intact antibodies while providing for tunable clearance, reduce serum half-life and potentially improved tumor penetration. Engineered PSCA minibodies and diabodies for both optical and PET imaging of prostate, bladder, and pancreatic cancers were developed, as was a PSMA-targeted minibody for imaging advanced prostate cancer. The use of optical fluorescent PSCA probes for intraoperative visualization of prostate cancer to eradicate more completely tumors was illustrated. The preclinical and early clinical development of PSCA and PSMA minibodies for PET imaging of highrisk and metastatic prostate cancer offers the potential for more sensitive and specific staging of disease and for setting up therapies targeting these antigens.
Martin Gleave (Vancouver Prostate Center, Vancouver, Canada) discussed co-targeting the AR and the adaptive stress pathway in CRPC. Molecular chaperons mediate stress responses by regulating autophagy and transcriptional survival networks. Two stress-activated cytoprotective chaperones, clustering (CLU) and Hsp27, are targets in clinical trials of CRPC.
CLU is transcriptionally regulated by stress-associated HSF1 and YB-1, retrotranslocating from the ER to cytosol to inhibit apoptosis by suppressing protein aggregation, p53-activating stress signals, and Bax, while enhancing Akt phosphorylation and transactivation of NF-kB, YB-1, and HSF-1. CLU supports tumor cell survival under stress conditions by facilitating autophagosome biogenesis. CLU confers treatment resistance in cancer, whereas CLU inhibition potentiates anticancer therapies, including enzobutamide, in preclinical models. The antisense oligonucleotide OGX.011 inhibits CLU and is in phase III trials of CRPC and lung cancer in combination with Taxol. Hsp27 expression is induced by hormone and chemotherapy and inhibits treatmentinduced apoptosis. Hsp27 inhibition may simultaneously suppress many pathways implicated in cancer progression and resistance to hormone-and chemotherapies. In a randomized phase II study of the Hsp27 inhibitor OGX-427 in patients with CRPC, preliminary results indicate PSA decline and freedom from progression at 12 weeks compared with prednisone controls. These results confirm, for the first time, single-agent activity for an Hsp27 inhibitor in cancer.
Summary
Hormones affect the incidence, natural history, and clinical outcome of common cancers. Clinical care of these tumors should be based upon a knowledge of molecular events that underlie biochemical, cell biological, and pathophysiological phenomena characteristic of each tumor in each patient. This symposium explored advances arising from a knowledge of the mechanisms of these phenomena. The major emphasis was on breast and prostate cancers.
In both tumor types, the response to hormones and hormone inhibitors was shown to be dependent on specific genes and their expression; gene mutations, chromatin state, and signaling pathways are all relevant in this respect.
Epigenetic regulation of gene expression and the epigenetic characterization of tumors are important. Knowledge of the molecular mechanisms of implementation of the genetic and epigenetic processes provides a basis for the development of new therapies that may be effective in specific patients or in a restricted group of patients. Indeed, the genome and related mutations take increasing importance in the treatment design for many tumors, including breast and prostate neoplasms.
Information discussed at the meeting supported the concept of cancer stem cells; clarification of phenomena involved in determining the decision of these cells about their fate provides leads for the development of new therapies. The utilization of engineered mini antibodies against stem cell antigens can improve the identification of these cells by fluorescence and also indicates the possibility of designing specific anti-stem cell treatments.
A functional cooperation between ER and HIF is a new area to be exploited for therapeutic intervention.
Tumor survival mechanisms in the face of metabolic stress must include consideration of the fact that protein synthesis is using much energy and that autophagy conserves energy. Mechanisms causing energy consumption and affecting tumor growth should be useful sites for the design of new therapies.
Altered DDR enzymes may also represent sites for therapeutic intervention; patients should be identified with altered DNA repair for suitable personalized treatments.
In conclusion, this symposium gave an integrated view of the role of a number of molecular factors and pathways in determining hormonal effects on the growth, and the growth inhibition by, and resistance to, inhibition of hormone function, of breast and prostate cancers; many of the phenomena discussed are of relevance to other types of tumors. Indeed, the meeting provided many promising leads for the development of new therapies and the achievement of the so-called personalized or precision medicine. 
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